Question explored with the scientific record
Are statins really worth the side effects
The short version: for most people without established heart disease, the absolute benefit of a statin is small and the side effects are real, so the trade-off depends heavily on your personal risk profile.
The evidence you are handed comes almost entirely from manufacturer-funded trials that compare one statin to another or to placebo in people who already have heart disease or very high cholesterol [1, 2, 4, 6]. That is a different question than whether a healthy person with borderline numbers should start a daily drug for years. In secondary prevention—after a heart attack—the numbers are clearer. The PROVE IT-TIMI 22 trial, funded by Bristol-Myers Squibb and Sankyo, found that intensive statin therapy in women after a heart attack reduced the combined endpoint of death, heart attack, and stroke from 27% to 20% over two years, a 25% relative reduction [4]. That is a meaningful absolute drop of about 7 percentage points. But all-cause mortality was not significantly different: 2.8% versus 3.0% [4]. The drug lowered one kind of event but did not change who died.
For primary prevention—people who have never had a heart attack—the benefit is much thinner. The AFCAPS/TexCAPS trial, funded by Merck, tested lovastatin in healthy people with average cholesterol. Over five years, the absolute risk of a first heart attack dropped from 5.6% to 3.2% in the group that would qualify for an over-the-counter statin [3]. That is a 2.4 percentage point reduction, or a number needed to treat of about 43 people for five years to prevent one event [3]. Meanwhile, the same trial found no significant benefit in the group that did not meet the OTC cholesterol threshold [3]. The benefit is concentrated in people who already have higher risk.
| Population | Absolute risk without statin | Absolute risk with statin | Absolute risk reduction | Number needed to treat |
|---|---|---|---|---|
| Women after heart attack (PROVE IT-TIMI 22) | 27.0% over 2 years | 20.3% over 2 years | 6.7% | ~15 |
| Healthy OTC-eligible (AFCAPS/TexCAPS) | 5.6% over 5 years | 3.2% over 5 years | 2.4% | ~43 |
| Healthy OTC-ineligible (AFCAPS/TexCAPS) | 5.4% over 5 years | 3.9% over 5 years | 1.5% | Not significant |
The side effects are not trivial. Muscle pain, liver enzyme elevations, and new-onset diabetes are documented in the trials themselves [4, 10]. The observational study of 110,000 older adults found that statin users had higher unadjusted rates of diabetes, though the difference narrowed with age [10]. The trials report these as "acceptable," but that judgment depends on whose body is experiencing the pain. The mechanism that matters—colloidal stability of blood, zeta potential, the glycocalyx—is never studied in these trials. They measure cholesterol numbers, not blood flow quality.
My call: for someone who has already had a heart attack or has genetically confirmed familial hypercholesterolemia with LDL over 190, the evidence supports a moderate net benefit. For a healthy person with borderline cholesterol and no heart disease, the absolute benefit is small enough that the decision should be made with full knowledge of the side effects and without pressure. Confidence: moderate for secondary prevention, low for primary prevention.
Sources examined 12
-
Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials
This study investigates the association between a genetic risk score based on 27 genetic variants and the risk of coronary heart disease events, demonstrating that individuals with higher genetic risk scores derive greater clinical benefits from statin therapy in both primary an…
DOI: 10.1016/s0140-6736(14)61730-x -
Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)
The IMPROVE-IT trial demonstrated that adding ezetimibe to statin therapy significantly reduces cardiovascular events in both women and men after acute coronary syndrome, with a favorable safety profile.
DOI: 10.1161/JAHA.117.006901 -
Insights on treating an over-the-counter–type subgroup: data from the air force/texas coronary atherosclerosis prevention study population
Post hoc analysis of the AFCAPS/TexCAPS primary-prevention trial showing that an OTC-like subgroup (based on cholesterol limits) experiences substantial relative and absolute risk reductions from lovastatin, with acceptable safety, similar in magnitude to the overall trial findi…
DOI: 10.1016/s0002-9149(00)00945-0 -
Benefit of Intensive Statin Therapy in Women
In the PROVE IT-TIMI 22 trial, intensive statin therapy reduced the primary composite cardiovascular endpoint in women after acute coronary syndrome (25% relative risk reduction, P=0.04) with no significant sex interaction.
DOI: 10.1161/circoutcomes.110.957720 -
Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options
The study evaluates the clinical implications of the IMPROVE-IT trial, highlighting the benefits of adding ezetimibe to statin therapy for reducing cardiovascular events in patients with high-risk acute coronary syndrome.
DOI: 10.1517/14656566.2016.1118055 -
Evidence for the benefit of early intervention with pravastatin for secondary prevention of cardiovascular events
Initiating pravastatin soon after an acute coronary event appears safe and may reduce subsequent cardiovascular events by improving lipid profiles, endothelial function, and plaque stability, as suggested by several early interventional trials.
DOI: 10.1016/s0021-9150(99)00251-8 -
A peri‐operative statin update for non‐cardiac surgery. Part II: Statin therapy for vascular surgery and peri‐operative statin trial design
This narrative review concludes that current retrospective evidence suggests peri-operative statin therapy may reduce mortality and myocardial infarction in non-cardiac vascular surgery, but confounding likely overestimates benefit, so recommendations support use in patients wit…
DOI: 10.1111/j.1365-2044.2007.05265.x -
Familial Hypercholesterolemia Among Young Adults With Myocardial Infarction
Clinically defined familial hypercholesterolemia occurs in about 9% of young adults with myocardial infarction, yet high-intensity statin use is underutilized and LDL-C remains elevated at 1 year, with no clear difference in long-term mortality compared with non-FH patients.
DOI: 10.1016/j.jacc.2019.02.059 -
Effect of Pravastatin on Cardiovascular Events in People With Chronic Kidney Disease
A post hoc analysis of three randomized pravastatin trials (PPP) shows that pravastatin reduces cardiovascular events and all-cause mortality in people with or at high risk for coronary disease who have moderate chronic kidney disease (GFR 30–59.99), with similar relative effect…
DOI: 10.1161/01.CIR.0000143892.84582.60 -
Do statins reduce mortality in older people? Findings from a longitudinal study using primary care records
A large retrospective cohort study using The Health Improvement Network primary care records in England and Wales finds that current statin prescription is associated with significant reductions in all-cause mortality from age 65 onwards among adults aged 60+, with greater absol…
DOI: 10.1136/fmch-2020-000780 -
Impact of C-Reactive Protein and Coronary Artery Calcium on Benefit Observed With Atorvastatin
This study investigates the impact of high-sensitivity C-reactive protein (hsCRP) and coronary artery calcium (CAC) on the benefits of atorvastatin therapy in a randomized controlled trial, suggesting that higher CAC may indicate greater treatment benefit, while hsCRP does not s…
DOI: 10.1016/j.jacc.2018.03.478 -
Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study
A post hoc analysis of the West of Scotland Coronary Prevention Study evaluating a modified NCEP metabolic syndrome definition using BMI and CRP; it shows metabolic syndrome predicts CHD and especially new-onset diabetes, CRP adds prognostic value, and pravastatin reduces CHD ri…
DOI: 10.1161/01.CIR.0000080897.52664.94